The Stop TB Partnership dedicates the call for the 2024 Kochon Prize to all the innovators in TB.
18 December 2024, Geneva, Switzerland - Stop TB Partnership is pleased to launch the call for nominations for the 2024 Kochon Prize. To end TB by 2030, the TB response requires an environment that promotes R&D, innovation, and one that paves the way for rapid adoption and improved access for new tools and innovative approaches and therefore leads to impact.
This year’s Kochon Prize will award people, teams or organizations that, day by day demonstrate how to successfully ensure access for people with TB to the latest new tools, innovations and innovative approaches that are leading to impact on the UNHLM targets. We must recognize their efforts to embrace novelty, be early adopters and innovators, and work towards ending TB.
Who can be nominated (including collaborations between the below)
- Government:
- Teams in Ministries of Health
- National TB Programmes
- Laboratories
- Private sector innovators
- Private / public sector partnerships
- Community, Civil Society and NGOs
Nomination Period and Process
The period for nominations begins on 18 December 2024. The online nomination form must be completed no later than 1 February 2025, 6:00 PM (Geneva time).
The nomination process is an online process. To access the nomination platform, click Stop TB Partnership | Kochon Prize Nomination Form
Nominations requirements:
- A nomination form requires the nominator(s) to answer 3 questions.
- Support letter from the nominator. The letter can also be from (endorsed by) multiple people.
Selection Process
For details on the selection criteria and criteria click here.
Award Announcement and Ceremony
The 2024 Kochon Award ceremony will take place in Q1/Q2 2025.
The Kochon Foundation
Funded by the Kochon Foundation, a non-profit foundation based in the Republic of Korea, the USD 65,000 prize is the largest prize devoted to TB. The Kochon Prize was established in 2006 in honour of the late Chairman Chong-Kun Lee, founder of the Chong Kun Dang Pharmaceutical Corporation and Kochon Foundation in Korea, who was committed throughout his career to improving access to low-cost lifesaving antibiotics and anti-TB drugs. More information on the Kochon Prize can be found here.
